Skip to main content

Novel Rx

    Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
    RT @Janetbirdope: #Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor progno
    10 months 1 week ago
    #Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor prognosis 3 #lupus #nephritis - treat early with #belimumab or #voclosporin and more Rx in #RCTs #gamechanger https://t.co/JHQHu91tud
    EULAR 2023 Day 4 Recap
    Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…
    Targeted therapies in Sjogren’s syndrome: are we close?

    There is a clear unmet need for new and effective therapies
    10 months 1 week ago
    Targeted therapies in Sjogren’s syndrome: are we close? There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies. https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2
    T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.  In POS0009, Anang et al. studied T-cell receptor repertoire (…
    There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.   Therapeutic development in pSS appears to…